Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease)PHERNAMBUCQ, E. C. J; BIESMA, B; SMIT, E. F et al.British journal of cancer. 2006, Vol 95, Num 4, pp 470-474, issn 0007-0920, 5 p.Article

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancerSMIT, E. F; FOKKEMA, E; BIESMA, B et al.British journal of cancer. 1998, Vol 77, Num 2, pp 347-351, issn 0007-0920Article

A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapyBIESMA, B; SMIT, E. F; POSTMUS, P. E et al.Lung cancer. 1999, Vol 24, Num 2, pp 115-121, issn 0169-5002Article

Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin―gemcitabine or carboplatin―paclitaxel: NVALT-3 a phase III studyBIESMA, B; WYMENGA, A. N. M; GROEN, H. J. M et al.Annals of oncology. 2011, Vol 22, Num 7, pp 1520-1527, issn 0923-7534, 8 p.Article

Serotonin, catecholamines, histamines, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumorsKEMA, I. P; DE VRIES, E. G. E; SLOOFF, M. J. H et al.Clinical chemistry (Baltimore, Md.). 1994, Vol 40, Num 1, pp 86-95, issn 0009-9147Article

Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancerBIESMA, B; POKORNY, R; KOVARIK, J. M et al.Cancer research (Baltimore). 1993, Vol 53, Num 24, pp 5915-5919, issn 0008-5472Article

Recombinant interferon alpha-2b in patients with metastatic apudomas : effect on tumours and tumour markersBIESMA, B; WILLEMSE, P. H. B; MULDER, N. H et al.British journal of cancer. 1992, Vol 66, Num 5, pp 850-855, issn 0007-0920Article

Negligible influence of comorbidity on prognosis of patients with small cell lung cancer : A population-based study in the NetherlandsJANSSEN-HEIJNEN, M. L. G; LEMMENS, V. E. P. P; VAN DEN BORNE, B. E. E. M et al.Critical reviews in oncology/hematology. 2007, Vol 62, Num 2, pp 172-178, issn 1040-8428, 7 p.Article

COPD in cancer patients : Higher prevalence in the elderly, a different treatment strategy in case of primary tumours above the diaphragm, and a worse overall survival in the elderly patientVAN DE SCHANS, S. A. M; JANSSEN-HEIJNEN, M. L. G; BIESMA, B et al.European journal of cancer (1990). 2007, Vol 43, Num 15, pp 2194-2202, issn 0959-8049, 9 p.Article

Docetaxel and cisplatin as induction chemotherapy in patients with pathologically-proven stage IIIA N2 non-small cell lung cancer : A phase II study of the european organization for research and treatment of cancer (EORTC 08984)BIESMA, B; MANEGOLD, C; SMIT, H. J. M et al.European journal of cancer (1990). 2006, Vol 42, Num 10, pp 1399-1406, issn 0959-8049, 8 p.Article

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatmentWACHTERS, F. M; GROEN, H. J. M; BIESMA, B et al.British journal of cancer. 2005, Vol 92, Num 1, pp 15-20, issn 0007-0920, 6 p.Article

Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy : a dose-finding studyPOSTMUS, P. E; GIETEMA, J. A; DAMSMA, O et al.Journal of clinical oncology. 1992, Vol 10, Num 7, pp 1131-1140, issn 0732-183XArticle

A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 studyAERTS, J. G; CODRINGTON, H; LANKHEET, N. A. G et al.Annals of oncology. 2013, Vol 24, Num 11, pp 2860-2865, issn 0923-7534, 6 p.Article

Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacyHUISMAN, C; BIESMA, B; POSTMUS, P. E et al.British journal of cancer. 2001, Vol 85, Num 10, pp 1456-1461, issn 0007-0920Article

Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study. EditorialTJAN-HEIJNEN, V. C. G; POSTMUS, P. E; LEGRAND, C et al.Annals of oncology. 2001, Vol 12, Num 10, pp 1339-1340, issn 0923-7534, 12 p.Article

Effects of hematopoietic growth factors on chemotherapy-induced myelosuppressionBIESMA, B; VELLENGA, E; WILLEMSE, P. H. B et al.Critical reviews in oncology/hematology. 1992, Vol 13, Num 2, pp 107-134, issn 1040-8428Article

Effects of interleukin-3 after chemotherapy for advanced ovarian cancerBIESMA, B; WILLEMSE, P. H. B; MULDER, N. H et al.Blood. 1992, Vol 80, Num 5, pp 1141-1148, issn 0006-4971Article

Carboplatin and paclitaxol (Taxol) as an induction regimen for patients with biopsy-proven stage IIIA N2 non-small cell lung cancer: an EORTC phase II study (EORTC 08958)O'BRIEN, M. E. R; SPLINTER, T; LEGRAND, C et al.European journal of cancer (1990). 2003, Vol 39, Num 10, pp 1416-1422, issn 0959-8049, 7 p.Article

Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinomaTJAN-HEIJNEN, V. C. G; BIESMA, B; FESTEN, J et al.Journal of clinical oncology. 1998, Vol 16, Num 8, pp 2708-2714, issn 0732-183XArticle

A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinomaDE VRIES, E. G. E; BIESMA, B; WILLEMSE, P. H. B et al.Cancer research (Baltimore). 1991, Vol 51, Num 1, pp 116-122, issn 0008-5472, 7 p.Article

Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapyDE VRIES, E. G. E; WILLEMSE, P. H. B; BIESMA, B et al.Lancet (British edition). 1991, Vol 338, Num 8765, pp 517-518, issn 0140-6736Article

Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and feverBIESMA, B; DE VRIES, E. G. E; WILLEMSE, P. H. B et al.European journal of cancer (1990). 1990, Vol 26, Num 9, pp 932-936, issn 0959-8049Article

Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975EFFICACE, F; BOTTOMLEY, A; MANEGOLD, C et al.Annals of oncology. 2006, Vol 17, Num 11, pp 1698-1704, issn 0923-7534, 7 p.Article

Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923)TJAN-HEIJNEN, V. C. G; CALEO, S; DEBRUYNE, C et al.Annals of oncology. 2003, Vol 14, Num 2, pp 248-257, issn 0923-7534, 10 p.Article

The value of [¹⁸F]fluoro-2-deoxy-n-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatmentHOEKSTRA, C. J; STROOBANTS, S. G; HOEKSTRA, O. S et al.Lung cancer. 2003, Vol 39, Num 2, pp 151-157, issn 0169-5002, 7 p.Article